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Abstract: Cervical cancer is the third most common cause of cancer-related death in 
women worldwide. Infection with high-risk human papillomavirus (HPV) is established as 
the cause of cervical carcinoma, therefore, high risk HPV detection may have prognostic 
significance for the women who are at increased risk of disease progression. The paucity of 
data on the incidence of cervical cancer in Pakistan makes it difficult to determine disease 
burden. Even less information is available regarding the prevalent HPV strains in cervical 
specimens collected from this region. Cervical cancer is a neglected disease in Pakistan in 
terms of screening, prevention, and vaccination. Identification and accurate genotyping of 
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the virus burden in cancer specimens is important to inform intervention policies for future 
management of HPV associated disease and to potentially stratify patients dependent on 
HPV status. In this study, detection and genotyping of HPV types 16 and 18 from 77 cervical 
specimens were carried out. Consensus primers GP5+/GP6+, which detect 44 genital HPV 
types, and type specific primers (TS16 and TS18) were used in conjunction with newly 
designed type specific primers. Using a combination of these methods of detection, a total 
of 94.81% (95% CI ±4.95) of cervical lesions were positive for HPV. Single infections of 
HPV16 were detected in 24.68% (95% CI ±9.63) of total samples and HPV18 was found in 
25.97% (95% CI ±9.79) samples. Interestingly, a high proportion of samples (40.26%, 95% 
CI ±10.95) was positive for both HPV16 and 18, indicating a higher incidence of  
co-infection than previously reported for similar ethnic regions. The HPV genotype of 
3.90% of HPV positive samples remained undetected, although these samples were 
positive with the GP5+/GP6+ primer set indicating infection with an HPV type other than 
16 or 18. These data indicate that the overall incidence of high risk HPV infection in 
cervical cancer and intraepithelial neoplasia specimens in Punjab, Pakistan is in line with 
the worldwide prevalence, but that the incidence of HPV16 and 18 co-infections in our 
cohort is higher than that previously reported.  
Keywords: HPV; prevalence; Pakistan; cervical cancer  
 
1. Introduction 
Cervical cancer is recognized as the third most common type of cancer in women worldwide and 
the second most prevalent cancer type and cause of cancer-related mortality in women in developing 
countries [1]. High-risk human papillomavirus (HPV) infection has been established as the main cause 
of cervical cancer [2]. Over 200 types of HPV are predicted to exist [3], including 30 types that are 
sexually transmitted and result in cervical infections [4]. Based on the frequency of detection in 
cervical cancer, HPV genotypes are sub-divided into high-risk HPV types (16, 18, 31 and 45), 
intermediate-risk types (33, 35, 39, 51, 52, 56, 58, 59, and 68) and low-risk types (6, 11, 42 and 44) [5].  
Most of the HPV-induced changes in cervical cells are transient and about 90% of them regress 
spontaneously within 12 to 36 months as the immune system eliminates the virus [4]. Papanicolaou 
(Pap) smear screening has played a significant role in the diagnosis of pre-malignant and malignant 
lesions in the cervix and has decreased the associated mortality rate in countries that have a robust 
screening program in place, however such screening programs in developing countries are limited or 
non-existent [1]. Since persistent infection with high-risk HPV types can result in cervical 
intraepithelial neoplasia (CIN) of different grades and invasive cancer within several years [6], and 
progression to cancer can be prevented by early detection of abnormalities and subsequent treatment, it 
is important to establish cost effective, sensitive, and accurate cervical screening protocols within 
routine clinical practice [7].  
Cervical cancer is the fourth most common cancer in Pakistan with an age standardized risk (ASR) 
per 100,000 women of 7.5, although these data come from a limited sampling of the population of 
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Pakistan (~1%) and the incidence of cervical cancer is likely to be on the rise [8,9]. These data indicate 
that while the cervical cancer burden in Pakistan is low compared to the worldwide ASR of 15.2 per 
100,000 women, in comparison to the risk within the Extended Middle East Region (ASR 3.4 per 
100,000 women), the cervical cancer burden is likely to be high [9]. The reasons for this are unclear, 
and further work is required to determine an accurate assessment of the cervical cancer burden and the 
HPV types associated with cancer development in Pakistan. Indeed, the role of HPV in cervical cancer 
in the Pakistani population has not been broadly studied. The only epidemiological data that has been 
reported was collected from patients from Karachi, Sindh [10–12]. However, these studies report 
conflicting results with HPV detected in 18%, 98.3%, and 92.2% of cervical cancer specimens, 
respectively [10–12]. Hence, there is a lack of consistent data on the prevalent HPV genotypes in 
Karachi and no available data on HPV prevalence in cervical cancer and neoplasia specimens in 
Punjab, Pakistan. While the incidence of cervical cancer in developed countries is declining, consistent 
with the introduction of rigorous cervical screening programs, successful treatment strategies, and 
vaccination practices, such interventions have yet to be implemented in Pakistan.  
Organized biobanking in Pakistan is a very reasonable concept in the pathology of the cervix as 
slides and formalin fixed paraffin embedded blocks are routinely stored for the period of 5 to 10 years 
for a number of reasons [13]. Polymerase chain reaction (PCR) is an efficient tool for the detection of 
different pathogens such as HPV in these stored samples [14]. The present study was conducted using 
paraffin embedded and retrospective cervical cancer tissues of patients from different areas of Punjab, 
Pakistan in order to determine the prevalence of HPV infection in cervical cancer specimens and the 
relevant HPV genotypes associated with disease.  
2. Materials and Methods  
2.1. Sample Collection 
A total of 74 formalin-fixed paraffin-embedded samples of cervical cancer tissue biopsies was 
collected from major hospitals in Punjab, Pakistan; Shifa International Hospital (SIH), and Pakistan 
Institute of Medical Science (PIMS), Islamabad (n = 13), Nishter Hospital (NH), Multan (n = 16), 
Allied Hospital (AH), Faisalabad (n = 11), Mayo Hospital (MaH), Lahore (n = 21), Holy Family 
Hospital (HFH) and Military Hospital (MH), Rawalpindi (n = 16). The samples were taken from 
patients aged 25–70 years (with mean age 46 and median age 50, where ages were known) who were 
treated during the period of January 2007–June 2010. Consent of the patient for the use of their 
samples for research purpose was taken (reviewed by NUST, Islamabad, Pakistan). 
Fresh samples were obtained from patients attending the Military Hospital (MH), Rawalpindi. All 
samples (two uterine cervix biopsies and one hysterectomy) were diagnosed for cervical cancer by the 
resident consultant histopathologist of the institute. The cervix was excised as part of their treatment 
and stored in phosphate buffer saline (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4, 
pH 7.4) immediately following removal. 
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2.2. DNA Extraction from Formalin Fixed Paraffin Embedded (FFPE) and Fresh Tissue Samples 
Prior to sectioning, tissue blocks were placed at −20 °C for 1 hour. Sections of 5–20 μm were cut 
from tissue biopsy samples on a microtome (CUT 6062, SLEE Mainz) using disposable blades and 
placed in 1.5 mL Eppendorf tubes. To avoid contamination of samples, blades were changed after 
every 10th sample and the microtome and blade were thoroughly cleaned with distilled water and 
ethanol between each specimen. Ten to twenty sections of each sample were taken and only the four to 
six sections were processed for PCR. In addition, an HPV negative tissue sample (atrophic 
endometrium) was sectioned between each of the cervical specimens. DNA was then extracted from 
the negative control samples alongside the cervical samples and amplified alongside the experimental 
samples with primer sets GP5+/6+, C16E7/C18E7, TS16/TS18. It was ensured that the PCR reactions 
in the negative control samples were negative in all cases included in our analysis.  
The sections were deparaffinized in 1 mL of xylene and shaken vigorously for 2 min followed by 
centrifugation at 12,200× g for 10 min. The supernatant was removed and the pellets were then washed 
again in xylene to avoid carryover of residual paraffin. The pelleted tissue was treated with 1 mL of 
100% (w/v) ethanol followed by centrifugation (16,200× g for 10 min) so as to remove residual xylene 
from the tissue. The supernatant was discarded and the tissue washed with 1 mL of 70% (w/v) ethanol 
before re-centrifugation at 16,200× g for 10 min. The supernatant was discarded and the tissue pellet 
air-dried. Following homogenization, the dry pellet was suspended in 400 μL digestion buffer (50 mM 
Tris-HCl, pH 8.5, 1 mM EDTA, and 0.5% Tween 20) and 0.25 mg/mL Proteinase K added (Invitrogen, 
Darmstadt, Germany). The mixture was incubated at 56 °C overnight. Following digestion, the 
samples were heated to 95 °C for 10 min and briefly centrifuged. The supernatant containing the DNA 
was transferred to a new 1.5 mL Eppendorf tube and stored at −20 °C for future use.  
Fresh biopsies (1 mm sections) were directly homogenized in 400 μL of digestion buffer followed 
by proteinase K treatment as mentioned above, prior to the storage of extracted DNA at −20 °C. 
2.3. DNA Extraction from HeLa Cells 
HeLa belong to an HPV18 positive cervical carcinoma cell line and were cultured in Dulbecco’s 
Modified Eagle Medium (DMEM) plus 10% fetal bovine serum. Cells were harvested by scraping and 
transferred to a 1.5 mL Eppendorf tube. The tube was centrifuged for 5 min at 12,200× g. The pellet 
was then resuspended in 200 μL of PBS (pH 7.4) and 2 mg/mL proteinase K was added. DNA was 
then isolated using QIAamp® DNA Mini Kit (Qiagen). All primer sets used in this study were tested 
with DNA extracted from HeLa cells to ensure that HPV16-specific primer sets were negative and the 
HPV18 primer sets were positive.  
2.4. Polymerase Chain Reaction 
DNA from each sample was amplified by PCR with the primer sets described in Table 1. A 20 μL 
reaction was assembled that contained 100–300 ng sample DNA, 1x Taq polymerase buffer 
(Fermentas), 0.1 mM deoxynucleotide triphosphate (dNTPs), 2.5 mM MgCl2, 1U of Taq polymerase 
(Fermentas), and 0.5 pmol of each primer. The PCR conditions for each primer set are detailed in  
Table 2. DNA from each sample was extracted in duplicate and each PCR reaction was performed in 
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duplicate for each independent extraction to ensure consistency of the results. PCR reactions were 
carried out individually for each primer set and the bands produced in five reactions with each primer 
set were sequenced to ensure specificity of amplification.  
The amplified products were analyzed on a 1.5% agarose gel, stained with ethidium bromide and 
visualized on a UV transilluminator. Beta-globin primers were used to check the quality of the DNA. 
The amplification was carried out in the presence of negative and positive controls; DNA from cervical 
cancer tissue samples positive for HPV (confirmed by sequencing) was used as a positive control for 
HPV16 and a negative control for HPV18-specific primer sets and DNA from HeLa cell line was used 
as positive control for HPV18 and a negative control for HPV16-specific primer sets. 
Table 1. Primers used for detection and genotyping of human papillomavirus (HPV) 16 and 18.  
Primer Sequence (5'-3') Target 
Product 
Size (bp) 
Reference 
PC03  ACACAACTGTGTTCACTAGC  β-globin 110 [15] 
PC04 CAACTTCATCCACGTTCACC 
GP5+ TTTGTTACTGTGGTAGATACTAC 
L1 150 [16] 
GP6+ GAAAAATAAACTGTAAATCATATTC 
New TS 16 
GGTCGGTGGACCGGTCGATG 
E6 HPV 16 96 [17] 
GCAATGTAGGTGTATCTCCA 
New TS 18 
CCTTGGACGTAAATTTTTGG 
CACGCACACGCTTGGCAGGT 
L1 HPV 18 115 [17] 
C16E7F GGGGAATTCGCATGGAGATACACCTACATTC 
E7 HPV 16 297 Current study 
C16E7R GGGCTCGAGTGGTTTCTGAGAACAGATGG  
C18E7F GGATCCGCATGGACCTAAGGCAACATT 
E7 HPV 18 318 Current study 
C18E7R GAATTCGCTGCTGGGATGCACACCA 
Table 2. Polymerase chain reaction (PCR) conditions for individual primer sets. 
Primer Name Hot Start 
Denaturation Annealing Extension 
Final Extension 
35 cycles 
PC03/PC04 94 °C, 4 min 94 °C, 30 s 54 °C, 45 s 72 °C, 30 s 7 min, 72 °C 
GP5+/GP6+ 94 °C, 4 min 94 °C, 30 s 45 °C, 45 s 72 °C, 30 s 7 min, 72 °C 
New TS 16 
94 °C, 4 min 94 °C, 45 s 58 °C, 45 s 72 °C, 30 s 7 min, 72 °C  
New TS 18 
C16E7  
C18E7 
3. Results and Discussion 
3.1. HPV Status of Cervical Cancer Biopsies 
Cervical cancer tissue biopsies and cervical intraepithelial lesions of different degrees were 
obtained from five different hospitals in Punjab as described in the materials and methods section. 
Tissue from patients with cervical lesions was obtained regardless of ethnic, social or economic 
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background. A total of 77 cervical cancer biopsies were histopathologically identified as squamous cell 
carcinoma (SCC; n = 43), adenocarcinoma (AC; n = 1), adenosquamous carcinoma (ASC; n = 3), high 
grade squamous intraepithelial lesion (HSIL; n = 11), low grade squamous intraepithelial lesion (LSIL;  
n = 4) and chronic cervicitis/metaplasia (n = 15) (Table 3). The histopathological distribution of our 
cervical cancer specimens is consistent with that previously reported in Karachi South, Pakistan [18]. 
Table 3. Histopathological classification and HPV status of cervical cancer biopsies  
SCC; Squamous cell carcinoma, AC; Adenocarcinoma, ASC; Adenosquamous carcinoma, 
HSIL; High grade intraepithelial lesion, LSIL; Low grade intraepithelial lesion,  
CIN; Cervical intraepithelial neoplasia. a Samples that were HPV positive (GP5+/GP6+), 
but genotype was not identified. 
Cytological diagnosis HPV16 + HPV18 + Co infection Unknown a HPV − Total 
Invasive Cervical Cancer (ICC) 
SCC 12 13 15 2 1 43 
AC - - 1 - - 1 
ASC 3 - - - - 3 
High Grade Neoplasia 
HSIL (CIN II, CIN III) 2 2 6 - 1 11 
Low Grade Neoplasia 
LSIL (CIN I) - - 3 1 - 4 
Chronic cervicitis/metaplasia 2 4 7 - 2 15 
Total 19 19 32 3  4 77 
To determine the HPV status of the cervical cancer biopsies obtained for this study, DNA was 
extracted and HPV status determined by PCR with GP5+/GP6+ consensus primers that are specific for 
the L1 region of the HPV genome and used for the detection of a large spectrum of 44 genital HPV 
types [16]. In addition, type specific (TS) genotyping primers as described by Baay et al. (1996) were 
used to specifically detect HPV16 (TS 16) and HPV18 (TS 18) [17]. TS 16 anneals to the E6 coding 
region of HPV16 and TS 18 anneals to the L1 coding region of HPV18. These primer sets were 
included in our study because they have been shown to be more sensitive than the broad spectrum GP 
consensus primers [17]. In an effort to further increase the PCR detection sensitivity, a third primer set 
was included that specifically anneals to the E7 coding region of HPV16 (C16E7) and HPV18 (C18E7).  
To eliminate the possibility of false positive and false negative results. several controls were 
included in all PCR reactions; a known HPV negative paraffin-embedded tissue was incised on the 
microtome between test samples. DNA was extracted from this negative control sample and analyzed 
by PCR. As expected, this sample was negative for HPV DNA amplification, although amplification of 
the β-globin gene was possible, verifying DNA quality of this sample. DNA extracted from HeLa cells 
was used as positive control for HPV18 amplification (Figure 1).  
Positive detection of the β-globin gene was achieved in all samples (data not shown). Positive 
detection of HPV DNA with the broad range detection primer set (GP) was achieved in 76.62% (59) of 
the samples (Figure 2), which is higher than the percentage of positive samples that has previously 
been achieved with the same primer set [17]. However, when the same samples were also tested with 
type specific primer pairs (TS16, TS18, C16E7 or C18E7), a total of 73 out of 77 (94.81%;  
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95% CI ±4.95) were found to be positive for HPV (Figure 2), which is consistent with the worldwide 
estimation of HPV infection in cervical carcinoma [19–21]. Only four of the biopsies were negative 
with all of the primer sets used in this study (5.19%). Of the 14 samples that were negative with the 
GP5+/GP6+ primers but positive with one or more of the type specific primer sets, 12 were positive 
with TS16 or TS18, six of which were also positive with either CS16 or CS18. Two samples were 
positive with our newly designed CS primer set but negative with all other primer sets used. Three 
samples were positive with the GP5+/GP6+ primer set that were negative with the type specific primer 
sets used, indicating that these samples were infected with an HPV type other than 16 or 18.  
Figure 1. HPV detection by PCR. A representative image is shown. The molecular weight 
in base pairs (bp) is on the left (Lane 1). Lane 2: PCR reaction using TS18 primers and 
template DNA extracted from HeLa cells (positive control). Lane 3 is the negative control 
for the PCR reactions using template DNA extracted from a known HPV negative tumor 
biopsy with primer set GP5+/6+. All primer sets were tested with the negative control 
DNA alongside each PCR reaction performed (not shown). Lane 4 is the L1 amplicon 
produced by using GP5+/6+ primers in an HPV16/18 positive squamous cell carcinoma 
(SCC) lesion. Lanes 5 and 6 are the amplicons generated from HPV16 using TS16 and 
E716 primers, respectively, from DNA extracted from the same lesion as in Lane 4. This 
lesion was also positive with HPV18 specific primer sets (not shown). Lanes 7 and 8 are 
HPV18-specific amplicons produced with TS18 and E718 primers sets, respectively, from 
DNA extracted from an HPV18 positive SCC lesion. Amplified DNA bands were 
sequenced using the forward primer for each reaction to ensure amplification of  
type-specific HPV DNA.  
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In contrast to our results, a recent study conducted in Karachi, Pakistan concluded that HPV might 
not be the major cause of SCC of the cervix, as only 18% of SCC samples were found to be HPV positive 
[10]. However, the study by Yousuf et al. was limited to the use of GP5+/6+ consensus primers and a 
Seegene Assay (Seeplex Genotyping Kit). We and others have demonstrated that GP5+/6+ is less 
sensitve than other detection methods. In another study also using GP5+/6+ -mediated PCR detection 
followed by reverse-line blot hybridisation of the PCR products it was shown that the prevalence of 
HPV infection was low in the general population in Pakistan (2.8% in a cohort of healthy married 
women enrolled in a cervical screening program), but invasive cervical carcinoma (ICC) was primarily 
attributed to HPV infection (92.2%) [12]. Although these figures are in line with our data, the overall 
proportion of HPV positive carcinomas in our study is higher, presumably due to increased sensitivity 
with the range of PCR methods used. Importantly, a further study conducted in Karachi by Khan et al. 
(2007) [11] supports our data since a strong relationship between HPV infection and cervical cancer 
among Pakistani women was demonstrated: 98% of samples were HPV positive. 
Figure 2. Detection of HPV in cervical lesions using alternative primer sets. Positive  
HPV detection using the broad range primer set GP5+/GP6+ was determined in 59 out  
of 77 samples. Sixty-four out of 77 samples were positive with TS primer sets and 53 out  
of 77 samples were positive with CS primer sets. In total, 73 out of 77 samples were 
positive with one or more primer sets, indicating an overall HPV prevalence of 94.81% in 
the cervical lesions tested. 
 
Analysis of samples with genotype specific primers revealed that HPV16 infection occurred either 
as a single infection or co-infection in 64.94% of samples, and HPV18 was detected in 66.23% of 
samples. Nineteen (24.68%; 95% CI ±9.63) of the samples were positive for HPV16 alone and 20 
(25.97%; 95% CI 9.79) of the samples were positive for HPV18 alone. These data suggest the 
distribution of HPV16 and 18 in cervical lesions might be different from that in other regions of 
Pakistan, as in South Karachi the prevalence of HPV16 infection has been reported to be associated 
with 75%–93% of carcinomas whereas HPV18 infection is associated with 4%–6.6% [11,12]. Studies 
in other countries of a similar cultural background have also reported a high prevalence of HPV16 
infection in cervical lesions collected from Iran (76% [22], 75% [23], 67.6% [24]) and Saudi Arabia 
(65.2% [25]) with a corresponding low HPV18 prevalence. However, another study conducted in Iran 
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showed that HPV18 was more commonly detected in cervical lesions than HPV16 (41% HPV18 
positive and 29.5% HPV16 positive) [26]. A high prevalence of HPV18 has also been reported in a 
study conducted in Indonesia with 44% of cervical cancer specimens testing positive for HPV16 and 
39% positive for HPV18 [27].  
Strikingly, 31 (40.26%; 95% CI ±10.95) samples in our study tested positive for both HPV16 and 
18, indicating co-infection (Figure 3). This is significantly higher than the low incidence of HPV16/18 
co-infection previously reported in Pakistan (<2%) [11,12] and in cervical cancers from Saudi Arabia 
(6.7%) and Jakarta, Indonesia (4.1%) [25,27]. However, a study in Thailand has indicated a high 
incidence of HPV16 (83.2%) and HPV18 (59.3%) in cervical cancer and lesions taken from women in 
four regions of Thailand and a high incidence of multiple infections, most notably 16/18 in 27.8% of 
samples and 16/18/11 in 20.4% of samples [28]. Co-infection with multiple HPV types was also noted 
in 15.3% of cervical specimens collected in Northwestern Iran but the majority of these cases of  
co-infection were HPV types 16 and 31 [24].  
Why the incidence of HPV18 in Pakistan is so much higher in Punjab (this study) than in South 
Karachi [11,12] is not clear, but the more sensitive methods of detection used in our study could in part 
account for this. However, it is entirely possible that the prevalence of viral types differs between these 
regions of Pakistan. Whether this has any impact on the cervical cancer incidence and outcomes in the 
different regions remains to be determined.  
Figure 3. Distribution of HPV types 16 and 18 in cervical lesions. Seventy-three out of 77 
samples tested were HPV positive, of which 31 were found co-infected with HPV16 and 
18, 19 were positive for HPV 16 alone and 20 were positive for HPV18 alone. Three 
samples were HPV postive but the HPV type could not be determined.  
 
3.2. Histopathology, Age, and HPV Status 
Correlation of histopathology with HPV status revealed that there was a high proportion of SCC 
(55.84% of samples, n = 43) that was equally associated with HPV16 (27.91%, n = 12) and 18 
(30.23%, n = 13) alone (Table 3, Figure 4). Interestingly, a further 34.88% (n = 15) of these cases were 
associated with HPV16 and 18 co-infection. Two further SCC samples were positive with the 
GP5+/GP6+ primers but were not positive with any of the type specific primers, indicating that these 
samples were infected with an HPV type other than HPV16 or 18. One SCC case was negative with all 
the primer sets used for analysis, indicating that this tumor was HPV negative. AC was much less 
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common (n = 1) and was only observed with co-infection of HPV16 and 18. ASC was also uncommon 
(n = 3) and was exclusive to HPV16 infection. Eleven of the samples were graded as HSIL, which was 
equally associated with HPV16 (n = 2) and 18 (n = 2) single infections. Six HSIL cases had a 
detectable HPV16 and 18 co-infection and one HSIL sample was negative with all primer sets, 
indicating that this sample was HPV negative. The number of LSIL samples in our cohort was low  
(n = 4) with the majority of these samples co-infected with HPV16 and 18 (n = 3). One of the LSIL 
samples was negative for HPV DNA in all of the assays used. There were 15 cases of chronic cervicitis 
and metaplasia, more than half of which were co-infected with HPV16 and 18 (n = 7) and two were 
negative with all primer sets used.  
Figure 4. Genotypic distribution of HPV according to histopathological diagnosis. The 
incidence of SCC was higher and associated with HPV16, HPV18 and co-infection. The 
incidence of AC, ASC and LSIL were low. HSIL, chronic cervicitis (Cc)/metaplasia has a 
moderate incidence and were associated with higher incidence of co-infection in majority 
of cases as compared to HPV16 and 18 infection alone. 
 
 
Histopathological diagnosis was correlated with age and HPV status (Table 4, Figure 5). The 
overall age distribution for cancer incidence was 21 to 80. The age groups 21–30 and 71–80 only have 
few cases of cancer with the majority of cases in women aged between 31 and 70. Women aged 
between 41–50 had the highest incidence of cervical disease, which is consistent with the worldwide 
age distribution for cervical carcinoma [4].  
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Table 4. HPV16 and 18 prevalence in cervical cancer biopsies with age distribution. 
Age Group HPV16 + HPV18 + Co-infection 
Genotype 
Unknown 
HPV −  N 
21–30 1 1 - - - 2 
31–40 4 3 5 - - 12 
41–50 4 4 7 - - 15 
51–60 5 4 3 - - 12 
61–70 3 2 3 2 1 11 
71–80 1 - - - - 1 
Unknown 1 5 14 1 3 24 
Total 19 19 32 3 4 77 
Figure 5. Genotypic distribution of HPV in cervical carcinoma samples in correlation with 
age. The maximum incidence of cervical carcinoma was found in age group 41–50 
followed by the 31–40 and 51–60 age groups, respectively. The incidence of co-infection 
was also higher in age group 41–50, whereas, the incidences of HPV16 and 18 were higher 
in the 51–60 and 41–60 age groups, respectively. 
 
4. Conclusions 
To date the prevalence and genotyping of HPV in cervical cancer patients in Southern Punjab of 
Pakistan has not been studied. In our study, 77 cervical samples were tested for HPV presence and 
94.81% (n = 73) were found to be positive for HPV. The samples were also subjected to HPV 
genotype analysis by PCR with type specific primer sets; 19 samples (24.68%) were positive for HPV 
type 16 alone and 20 samples (25.97%) were positive for HPV type 18 alone. Thirty-one samples 
(40.26%) had a detectable co-infection with HPV16 and 18. This is the first study of its kind, which 
highlights the HPV prevalence in cervical cancers in this region. According to the International 
Association for Research in Cancer (IARC), the most prevalent high risk HPV genotypes which infect 
the cervix are: HPV16 (53%), HPV18 (15%), HPV45 (9%), HPV31 (6%), and HPV33 (3%) [29]. 
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Reports on the prevalence of HPV genotypes in cervical cancer consistently show that HPV16 
infection is the most common and that infection with HPV18 is the second most common [19,29]. Our 
results however demonstrate that the distribution of single HPV 16 and 18 infections in cervical lesions 
collected from Southern Pakistan does not follow this pattern; infection with HPV18 alone is as 
common as infection with HPV16 alone. Furthermore, the worldwide incidence of HPV16 and 18  
co-infection is significantly lower than that detected in our samples [25,27,30,31]. While we 
acknowledge that the impact of our results would be enhanced by an increase in sample size and 
secondary validation of co-infection, such as Southern blot, at present neither of these options is 
available in the local setting. Nonetheless, with the measures we have taken to control for  
cross-contamination and non-specific amplification of related HPV species, we believe that our data 
are valid and provide insight into the prevalence of HPV16 and 18 in cervical lesions in a previously 
unstudied geographical region.  
The importance of high risk HPV infection in the development of cervical cancer has been clearly 
demonstrated [32]. Preventing the transmission of high risk HPV is difficult, therefore screening for 
persistent HPV infection and cytological analysis are the main defenses against cervical cancer and are 
widely practiced in the developed world [33]. In developed countries, routine screening by examination 
of Pap smears and cervical cytology are carried out. However, this method of screening is not entirely 
accurate for the detection of cancer and pre-cancerous lesions, requiring many rounds of screening to 
achieve programmatic effectiveness [34]. Since accurate virus typing plays an important role in 
clinical management of the disease [35], the Food and Drug Administration (FDA) has approved a 
PCR-based test, Cervista HPV HR, for screening of HPV infections in the general population.  
The general population and health care practitioners in Pakistan have little information and 
understanding about HPV infection, HPV associated cancers, their prevention, and HPV vaccination. 
Here, the only way to diagnose cancerous or pre-cancerous lesions is by means of Pap smear test, 
which as mentioned above is not altogether precise and accurate. In addition, Pap smears are not 
performed regularly and international recommendations are not adhered to. The inadequate diagnostic 
techniques, changing moral values, and lack of awareness are the main reasons for the current gradual 
increase in the incidence of disease in the country.  
Epidemiological evidence suggests that regular cervical screening in adult females is important in 
the reduction of HPV-associated cervical disease [36]. Cervical carcinoma screening tools currently 
used in Pakistan are limited to Pap smears in self referred patients to look for abnormal cellular changes 
followed by visual inspection of the cervix using acetic acid staining if abnormal cells are found in the 
initial Pap smear [37]. A routine screening program does not exist. Since a strong connection between 
HPV infection and the development of cervical cancer and neoplasia has been found in this study, 
HPV typing could be used as an effective test to predict malignant progression. Timely detection of a 
high risk HPV infection would allow effective follow-up and better management of disease, since early 
intervention has been shown to diminish the disease burden [38]. The surveillance of HPV infections 
and the impact of vaccination is a critical element in the process of HPV vaccine introduction. Based 
on this need, an HPV detection and genotyping test is likely to be made commercial very soon in the 
Atta-ur-Rahman School of Applied Biosciences, National University of Sciences and Technology 
(ASAB, NUST) diagnostic laboratory with a view to provide facility to risk prone women (diagnosed 
with abnormal Pap smears) so HPV infection status can be confirmed.  
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